| Course | NR 546 Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner |
|---|---|
| Week | 6 |
| Paper type | Adverse effect brief |
| Length | About 1,120 words, 2 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | September 2026 |
Free sample paper for NR 546 Week 6
Adverse Effect Brief: Escitalopram 20 mg for a 41-Year-Old Adult Who Also Takes Sumatriptan and Ibuprofen, Narrowed to the Eight Effects That Decide Whether Treatment Continues
Student Name
College of Nursing, Chamberlain University
NR 546: Advanced Pharmacology: Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner
Instructor Name
Month Day, Year
Adverse Effect Brief: Escitalopram 20 mg for a 41-Year-Old Adult Who Also Takes Sumatriptan and Ibuprofen, Narrowed to the Eight Effects That Decide Whether Treatment Continues
Who This Brief Is For
This brief covers escitalopram at 20 mg daily for one patient: a 41-year-old teacher with major depressive disorder with anxious distress, diarrhea-predominant irritable bowel syndrome, migraine treated with sumatriptan about twice a month, occasional ibuprofen for back pain and a body mass index of 32. The patient is not pregnant, with an intrauterine device for contraception. There is no heart disease and no seizure history. Age matters: at 41, the patient is outside the group under 25 for whom the boxed warning on suicidal thinking applies, and below the age at which hyponatremia becomes a common concern. Those facts change which effects belong in the brief.
How the Effects Were Selected
Escitalopram's product labeling lists dozens of adverse effects. This brief keeps eight, chosen on two axes at once: how likely the effect is in this patient, and how much it would matter to this patient. Common effects are kept if they are likely to lead the patient to stop treatment. Rare effects are kept if they are serious and this patient has a specific risk factor. Everything else is left out. A critical review of newer antidepressants noted that tolerability problems, including sexual dysfunction, weight change and discontinuation symptoms, are common and often underestimated in clinical trials (Carvalho et al., 2016), which argues for giving the common effects as much attention as the rare ones.
The selection also depends on the dose. At 20 mg, the effects most tied to serotonin, gastrointestinal upset and sexual dysfunction, are more likely than at 10 mg, while sedation remains uncommon. The brief was therefore written for the dose the patient is about to take, not the one already tolerated.
Common Effects That Decide Adherence
1. Gastrointestinal upset and loose stools. Presentation: nausea early in treatment and again for a few days after each dose increase; loose stools, which may worsen this patient's irritable bowel symptoms. Detection: asked at each contact. Action: take with food; the increase to 20 mg can be delayed a week if symptoms flare; loperamide as already used. If diarrhea becomes intolerable, return to 10 mg.
2. Sexual dysfunction. Presentation: reduced desire, delayed orgasm or anorgasmia; this patient already reports mild delay at 10 mg. Detection: a direct question at every visit, since patients rarely volunteer it. Action: if it becomes unacceptable, options include lowering the dose or adding or switching to bupropion, which has low rates of sexual dysfunction.
3. Sleep changes and activation. Presentation: insomnia or vivid dreams, or restlessness, especially early in treatment. Detection: asked at each contact. Action: if the dose is now taken in the evening and sleep worsens, move it back to the morning.
4. Discontinuation symptoms. Presentation: dizziness, irritability, flu-like feelings or electric-shock sensations after missed doses or abrupt stopping. This patient has missed doses and reports foggy Mondays. Detection: asked about missed doses. Action: adherence support; never stop suddenly; taper over one to two weeks if stopping.
Serious Effects Grouped Apart
5. Bleeding. Why included: selective serotonin reuptake inhibitors reduce platelet serotonin and increase bleeding risk, and a meta-analysis of observational studies found an increased risk of bleeding with these drugs, higher when combined with nonsteroidal anti-inflammatory drugs (Laporte et al., 2017). This patient uses ibuprofen. Presentation: unusual bruising, nosebleeds, black stools, vomiting blood. Action: prefer acetaminophen for back pain; if an anti-inflammatory is needed, use it briefly; urgent evaluation for any sign of gastrointestinal bleeding.
6. Serotonin toxicity with sumatriptan. Why included: a regulatory advisory warns of serotonin syndrome when triptans are combined with serotonergic antidepressants. A large study of patients prescribed both found definite serotonin syndrome to be very rare, only two definite cases across roughly 31,000 person-years of combined exposure (Orlova et al., 2018). The combination is therefore continued, with counseling. Presentation: agitation, sweating, tremor, muscle twitching, fever and diarrhea within hours of a triptan dose. Action: stop both drugs and seek emergency care.
7. Hypomania or mania. Why included: rare in a patient with no bipolar history, but serious. Presentation: reduced need for sleep with high energy, rapid speech, racing thoughts, unusual spending or risk-taking. Action: hold escitalopram and be seen within a day.
8. Worsening depression or suicidal thinking. Why included: although the boxed warning applies to those under 25, any patient with depression needs monitoring, and this patient reported passive death wishes at baseline. Presentation: new or worsening thoughts of death or self-harm, agitation or hopelessness. Action: same-day contact; emergency services or crisis line if there is intent or a plan.
Effects Left Out, and Why
QT prolongation is dose-related with escitalopram and relevant at 20 mg, but nothing in this patient's history involves the heart, and no other listed drug lengthens the QT interval, so it is noted in the record rather than counseled. Hyponatremia is mainly a risk in older adults and those on diuretics. Weight change is small in the short term; the patient's weight is recorded at each visit, which is enough.
Emotional blunting, a sense of feeling flat or less able to cry, is reported by some patients on these drugs. It is not in the main list because this patient has not described it, but it will be asked about if mood improves while enjoyment does not return.
What to Call About Now Versus Next Visit
Call or seek care now: thoughts of harming yourself; very high energy with little need for sleep; fever, sweating, shaking and muscle jerks after a migraine tablet; black stools or vomiting blood.
Tell us at the next visit: upset stomach or loose stools, changes in sexual function, sleep changes, dizziness after missed doses.
Counseling in the Patient's Words
"Most people who have side effects from this medicine have them early, and most of those settle. The ones I most want you to tell me about are changes in your sex life, because they are common and we have ways to help, and any worsening of your mood or thoughts of harming yourself, which I need to know about the same day. Use acetaminophen instead of ibuprofen for your back when you can. You can still use your migraine tablet, but if you ever feel shaky, sweaty and feverish after taking it, stop and get help right away."
References
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016). The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: A critical review of the literature. Psychotherapy and Psychosomatics, 85(5), 270-288. https://doi.org/10.1159/000447034
Laporte, S., Chapelle, C., Caillet, P., Beyens, M.-N., Bellet, F., Delavenne, X., Mismetti, P., & Bertoletti, L. (2017). Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacological Research, 118, 19-32. https://doi.org/10.1016/j.phrs.2016.08.017
Orlova, Y., Rizzoli, P., & Loder, E. (2018). Association of coprescription of triptan antimigraine drugs and selective serotonin reuptake inhibitor or selective norepinephrine reuptake inhibitor antidepressants with serotonin syndrome. JAMA Neurology, 75(5), 566-572. https://doi.org/10.1001/jamaneurol.2017.5144
NR 546 Week 6 instructions, in plain terms
This week asks for a focused brief on the adverse effects of a psychotropic medication for a particular patient or population. The prompt usually wants the population, the most important adverse effects with their presentation and management, monitoring, serious reactions and patient counseling. Name the population first, since age, pregnancy and comorbidity change which effects matter. Explain how you selected effects, weighing both how likely each is and how much it would matter to this person. For each effect, give how it presents, what detects it and what action follows. Group serious reactions apart so they are not lost. Explain what you left out and why. Separate what the patient should call about now from what can wait. Write counseling as you would say it. Cite safety evidence in APA 7.
Inside the NR 546 Week 6 example
The brief opens by describing the patient, a 41-year-old with irritable bowel syndrome, migraine treated with sumatriptan, occasional ibuprofen and obesity, and explains why age removes some effects from the list. A section explains the two-axis selection and the effect of the higher dose. Four common effects follow, each with presentation, detection and action: bowel upset, sexual dysfunction, sleep change and discontinuation symptoms. Four serious effects are grouped apart: bleeding with anti-inflammatory drugs, supported by a meta-analysis; serotonin toxicity with sumatriptan, with a large study showing it is very rare; mania; and suicidal thinking. A section explains what was left out, including QT effects and hyponatremia. The brief ends with call-now rules and plain counseling.
Reading the NR 546 Week 6 grading rubric
Adverse effect briefs are generally evaluated on relevance to the population, sound selection of effects, practical management of each, clear separation of serious reactions and effective counseling. Naming the population and explaining how effects were chosen shows the brief is written for someone real. Weighing both likelihood and impact, rather than seriousness alone, produces a usable document and is what instructors look for. Giving each effect its presentation, detection and action, without gaps, shows readiness to manage it. Grouping serious reactions apart protects them from being lost. Explaining what was left out shows judgment. Counseling in the patient's words and clear call-now instructions complete the brief, and APA 7 citations to safety evidence support its choices.
NR 546 Week 6 help from the desk
Briefs often copy a long list from the label, ranked by seriousness, which produces a document nobody can use. Select effects for this patient. Another weakness is omitting common effects because they are not dangerous, even though they drive patients to stop. Include the ones that matter to adherence. Some students list effects without saying how they would be detected or what would be done. Give all three. Avoid mixing rare emergencies into the middle of a list of nuisances. Check the patient's other medications for interactions, since those often decide which serious effects belong. Write counseling as spoken words, not jargon. Explain what you left out, so the reader knows it was a choice rather than an oversight.
Get a NR 546 Week 6 example written to your instructions
Send the Week 6 instructions along with the agent and population your section names, and a custom example is written in your required format and returned inside 24 to 48 hours. The first one is free. What you would actually hand to a patient of your own stays your call.
More NR 546 papers and PMHNP samples
- NR 546 Week 1: Antidepressant Timing Discussion
- NR 546 Week 2: Receptor Mechanism Write-Up
- NR 546 Week 3: Medication Selection Rationale
- NR 546 Week 4: Titration and Monitoring Plan
- NR 546 Week 5: Partial Response Case Analysis
- NR 546 Week 7: Medication Education Handout
- NR 546 Week 8: Psychopharmacology Case Paper
NR 546 Week 6 questions, answered
How many effects should the brief cover?
Few enough to be read in a minute, which usually means a handful of common ones and a short group of serious ones. Where your section sets a number, meet it by choosing rather than by extending down the list. A brief that covers six effects properly is more useful and scores higher than one covering twenty in a sentence each.
Do rare reactions belong if they are very unlikely?
Where the consequence is severe, yes, and that is exactly why ranking on likelihood alone fails. The test is what it would cost to miss it. Keep those entries grouped separately so they read as warnings rather than as items in a list, and give each one a clear action rather than only a description.
Should the brief be written for the patient or the prescriber?
Check the instructions, since sections differ and the two documents look different. A prescriber brief can use clinical terms and carries monitoring detail; a patient sheet needs plain wording, a reading level and clear instructions about when to call. Say which one you need when requesting an example, because converting between them is not a matter of editing.
Where can I find a free NR 546 Week 6 sample paper?
The eight-effect escitalopram brief is shown above as the NR 546 Week 6 sample, with every section open. If your patient takes a different medication, send us the details and a brief narrowed to the effects that matter can be drafted.
How many adverse effects should the NR 546 Week 6 brief include?
Only those likely or important for this patient, often six to ten. The sample keeps eight, four common and four serious, and explains what it left out.